Viewing Study NCT00742105

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:30 AM
Ignite Modification Date: 2026-06-07 @ 6:46 AM
Study NCT ID: NCT00742105
Status: TERMINATED
Last Update Posted: 2018-09-25
First Post: 2008-08-25
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Cancer View
None Solid Tumor View
None Advanced Solid Tumor View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PI3K View
None mTOR View
None Advanced solid tumor View
None Adult View